Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis

Inclusion Criteria: * Participants must be at least 18 years of age * Patients with end-stage renal disease on hemodialysis (including hemodiafiltration) for ≥3 months, receiving dialysis at least 9 hours a week and stable in the view of the investigator * Body weight of at least 50 kg * Male and/or female. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Exclusion Criteria: * Recent (\<6 months before screening) clinically significant bleeding * Hemoglobin (Hb) \< 9.0 g/dL at screening * Platelet count \< 100 x 10\^9/L * aPTT or PT \> ULN (upper limit of normal) * Hepatic disease associated with ALT \> 3x ULN, or total bilirubin \>2x ULN with direct bilirubin \> 20% of the total * Sustained uncontrolled hypertension (diastolic blood pressure ≥100 mmHg and/or systolic blood pressure ≥ 180 mmHg) * Known intracranial neoplasm, arteriovenous malformation or aneurysm * Known bleeding disorders e.g. von-Willebrand disease or Hemophilia A, B or C * Recent (\<3 months before screening) thromboembolic event, e.g. acute coronary syndrome, stroke or VTE (except dialysis access thrombosis) * Recent (\<3 months before screening) major surgery or scheduled major surgery during study participation * Scheduled living donor renal transplant during study participation * Persistent heart failure as classified by the New York Heart Association (NYHA) classification of 3 or higher * Receiving antiplatelet therapy except daily ASA ≤ 150 mg/day * Receiving anticoagulation in therapeutic doses, other than standard anticoagulation during the hemodialysis procedure